3D Medicines, Inc. (1244) AI Stock Analysis

• Market Cap: HK$2.09B
• Dividend Yield: N/A
• Average Volume (3M): 964.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.71
• Revenue Growth: -8.43%
• EPS Growth: 64.33%
• Country: HK
• Employees: 191
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 258,177,000
• 10 Day Avg. Volume: 1,257,949
• 30 Day Avg. Volume: 964,754
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$8.50
• Price Target Upside: 4.94% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: HK$9.50 ▲(17.28% Upside)

The stock score is primarily driven by strong technical momentum, with the stock trading well above key moving averages. However, significant financial performance challenges, including negative profitability and reliance on external financing, weigh heavily on the score. The valuation is also weak due to a negative P/E ratio and lack of dividend yield.

3D Medicines, Inc. Business Overview & Revenue Model

Company Description

3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and drug candidates for the treatment of patients with various cancers in Mainland China. It offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. The company's products in development pipeline include 3D189 for multi-indication tumor and is in phase III clinical trial; 3D229 (GAS6/AXL) for non-small cell lung cancer, ovarian cancer, and kidney cancer and is in phase III clinical trial; 3D1001 for the treatment of postoperative dental pain and tumor pain which is in phase II trial; 3D1002 for oncology pain and is in phase II trial; and 3D185, which is in phase I clinical trial for the treatment of locally advanced or metastatic solid tumors, as well as other products, such as 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumor, and 3D057 for multiple indications tumors. 3D Medcines Inc. was founded in 2014 and is headquartered in Qingdao, China.

How the Company Makes Money

3D Medicines, Inc. generates revenue through the development and commercialization of its proprietary drugs and therapeutic solutions. Key revenue streams include sales of approved pharmaceutical products, licensing agreements, and collaborations with other pharmaceutical companies and research institutions. The company may also receive milestone payments and royalties from partnerships and licensing deals as its drug candidates progress through clinical trials and reach the market. Strategic partnerships with healthcare organizations and research entities play a significant role in advancing its drug pipeline and expanding its market presence.

3D Medicines, Inc. Financial Statement Overview

Summary

3D Medicines, Inc. shows significant revenue growth but faces profitability challenges with persistent losses and negative operational margins. While the balance sheet has improved, reliance on external financing and negative cash flows suggest ongoing financial and operational challenges.

Income Statement

The company shows significant revenue growth from 2020 to 2024, with a strong increase in total revenue. However, the net income remains negative, indicating persistent losses. Gross profit margin is high, but negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The balance sheet shows a strong cash position with substantial cash equivalents and short-term investments. However, the company has a negative equity position until 2022, which improved in later years. The debt-to-equity ratio is concerning due to high leverage in earlier years, but it has improved recently.

Cash Flow

Operating cash flow has been negative, showing challenges in generating cash from core operations. Free cash flow is consistently negative, reflecting high capital expenditures and operational challenges. Financing cash flow is positive, indicating reliance on external funding.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	445.65M	634.95M	567.39M	60.26M	0.00
Gross Profit	371.74M	524.01M	525.18M	55.98M	0.00
EBITDA	-226.95M	-529.23M	-1.03B	-1.45B	-303.35M
Net Income	-182.66M	-524.70M	-1.02B	-1.43B	-635.38M
Balance Sheet
Total Assets	1.22B	1.43B	1.33B	1.06B	496.22M
Cash, Cash Equivalents and Short-Term Investments	840.98M	996.58M	942.03M	824.48M	414.26M
Total Debt	237.62M	282.43M	175.70M	58.74M	20.37M
Total Liabilities	512.54M	558.20M	436.65M	3.33B	1.77B
Stockholders Equity	785.06M	936.74M	943.00M	-2.24B	-1.27B
Cash Flow
Free Cash Flow	-255.94M	-150.74M	-332.76M	-433.46M	-289.48M
Operating Cash Flow	-210.58M	-144.41M	-278.78M	-377.08M	-278.33M
Investing Cash Flow	17.95M	-187.58M	-242.11M	-98.87M	-20.48M
Financing Cash Flow	-33.92M	304.51M	408.41M	840.08M	607.39M

3D Medicines, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1244, the sentiment is Positive. The current price of 8.1 is below the 20-day moving average (MA) of 8.19, above the 50-day MA of 7.50, and above the 200-day MA of 4.46, indicating a neutral trend. The MACD of 0.21 indicates Positive momentum. The RSI at 51.10 is Neutral, neither overbought nor oversold. The STOCH value of 16.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1244.

3D Medicines, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	56 Neutral	1.69B	208.57	4.76%	―	9.41%	-32.69%
1244	54 Neutral	HK$2.09B	―	-21.45%	―	-8.43%	64.33%
2126	54 Neutral	2.07B	-3.06	-50.52%	―	2.45%	2.58%
6628	53 Neutral	2.01B	-6.44	-38.62%	―	-57.84%	24.58%
2137	52 Neutral	1.51B	-3.69	-19.13%	―	0.00%	-41.48%
6998	51 Neutral	2.15B	92.12	0.00%	―	1447.56%	0.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

3D Medicines, Inc. Corporate Events

3D Medicines Reports Strong Progress and Global Expansion in H1 2025

3D Medicines Inc. reported significant progress in the first half of 2025, leveraging a recovering biotech-focused capital market in Hong Kong. The company achieved stable revenue and met key R&D milestones, with notable advancements in the commercialization of Envafolimab, its first commercialized product, which saw a 1.3% increase in sales revenue in China. The company presented multiple research achievements at the 2025 ASCO Annual Meeting, highlighting the efficacy and safety of Envafolimab in various cancer treatments. These developments underscore 3D Medicines’ commitment to innovation-driven growth and global expansion, marking a new chapter in its operational strategy.

The most recent analyst rating on (HK:1244) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on 3D Medicines, Inc. stock, see the HK:1244 Stock Forecast page.

3D Medicines Administers First Dose of Novel Cancer Drug

3D Medicines Inc. has successfully administered the first dose of its novel radioactive drug conjugate, 3D1015, in a human trial. This study aims to evaluate the safety and preliminary efficacy of the drug in patients with PSMA-positive metastatic castration-resistant prostate cancer, a group with significant unmet clinical needs. The trial will provide critical clinical evidence for dosage determination and risk management in future clinical trials, potentially impacting the company’s operations and positioning in the oncology drug development market.

The most recent analyst rating on (HK:1244) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on 3D Medicines, Inc. stock, see the HK:1244 Stock Forecast page.

3D Medicines Partners with CATUG Biotechnology to Enhance mRNA Therapy Development

3D Medicines Inc. has entered into a strategic cooperation agreement with CATUG Biotechnology to advance the development of TLNP-delivered in vivo CAR-T/NK therapies. This collaboration aims to combine 3D Medicines’ mRNA R&D platform and LNP delivery system with CATUG’s expertise in large-scale mRNA production, enhancing the company’s capabilities in targeted LNP delivery, cancer vaccines, and immune cell therapies. The agreement is expected to accelerate 3D Medicines’ expansion in mRNA research and support the clinical development and commercialization of its innovative therapeutic products.

The most recent analyst rating on (HK:1244) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on 3D Medicines, Inc. stock, see the HK:1244 Stock Forecast page.

3D Medicines Inc. Schedules Board Meeting for Interim Results and Dividend Consideration

3D Medicines Inc. has announced that its board of directors will meet on August 29, 2025, to approve the unaudited interim results for the first half of the year and discuss the potential payment of an interim dividend. This meeting is significant as it will provide insights into the company’s financial performance and potential shareholder returns, impacting its market positioning and investor relations.

3D Medicines Inc. Announces Withdrawal of Legal Proceedings

3D Medicines Inc., incorporated in the Cayman Islands, announced the withdrawal of civil proceedings initiated by Qingdao Hainuo against the company. The court approved the withdrawal, and Qingdao Hainuo will bear the associated fees of approximately RMB1.17 million. This development removes a potential legal hurdle for 3D Medicines, potentially stabilizing its market position and reassuring stakeholders.

3D Medicines Inc. Strengthens Stability with Strategic Agreement

3D Medicines Inc. has announced a strategic cooperation agreement with Qingdao Hainuo, aimed at resolving ongoing legal disputes and fostering future collaboration. The agreement, valued at RMB98.0 million, led to the withdrawal of civil proceedings and the discharge of a Preservation Order, thereby enhancing the company’s operational and financial stability.

3D Medicines, Inc. Enhances Operational Stability Through Strategic Cooperation

3D Medicines, Inc. has entered into a Strategic Cooperation Agreement with Qingdao Hainuo, a substantial shareholder of its subsidiary, to discharge a Preservation Order imposed by the Qingdao Intermediate People’s Court. This agreement, valued at RMB98.0 million, aims to improve the company’s financial flexibility and operational efficiency by unfreezing bank accounts and facilitating smoother day-to-day operations, thereby reinforcing the company’s financial stability.

3D Medicines Inc. Announces Successful AGM Resolutions

3D Medicines Inc. announced the successful passing of all resolutions at its Annual General Meeting held on June 30, 2025. Key resolutions included the appointment of Mr. Zhu Jinqiao as a non-executive director and the re-election of independent directors, along with the authorization for the board to manage share allotments and repurchases. These developments are poised to impact the company’s governance structure and operational strategies positively.

3D Medicines Inc. Announces Board Composition and Committee Assignments

3D Medicines Inc. has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The board has also established three committees: Audit, Remuneration, and Nomination, with specific directors assigned as members or chairpersons of these committees. This organizational structure aims to enhance corporate governance and operational efficiency, potentially impacting the company’s strategic direction and stakeholder relations.